Please use this identifier to cite or link to this item:
Title: Targeting Stealth liposomes in a murine model of human small cell lung cancer
Authors: Moreira, João N. 
Gaspar, Rogério 
Allen, Theresa M. 
Keywords: Pegylated liposome; Doxorubicin; Targeting; Antagonist G; Small cell lung cancer
Issue Date: 2001
Citation: Biochimica et Biophysica Acta (BBA) - Biomembranes. 1515:2 (2001) 167-176
Abstract: Tumor accumulation and therapeutic activity of Stealth liposomes loaded with doxorubicin (DXR) were examined in Balb/c nude mice xenografts inoculated subcutaneously with the human small cell lung cancer (SCLC) cell line, H69. Mice were treated with non-targeted liposomes (SL) or liposomes targeted with antagonist G coupled to the liposome surface (SLG). SLG showed 30-44-fold higher binding to H69 cells harvested from H69 xenografts than SL. At 48 and 72 h post injection, tumor accumulation of [125I]tyraminylinulin-containing liposomes was shown to be dependent on liposome size but independent of the presence of the targeting ligand. Maximum tumor uptake of either SLG or SL ranged from 2 to 4% of injected dose/g of tissue. In therapeutic studies, mice received three weekly injections of 3 or 6 mg free DXR/kg or 3 or 10 mg liposomal DXR/kg at initial tumor volumes of either 7 or 33 mm3. The therapeutic efficacy of DXR-containing SL or SLG was significantly improved over free DXR, but SLG did not improve anti-tumor efficacy relative to SL. Stealth liposomes containing DXR have potential as a therapy against human SCLC tumors.
DOI: 10.1016/S0005-2736(01)00411-4
Rights: openAccess
Appears in Collections:FFUC- Artigos em Revistas Internacionais

Files in This Item:
File Description SizeFormat
file34ded342f83c479f81bb36228c693307.pdf244.6 kBAdobe PDFView/Open
Show full item record


checked on Jan 2, 2022

Page view(s) 50

checked on Sep 16, 2022

Download(s) 50

checked on Sep 16, 2022

Google ScholarTM




Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.